Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (vol 20, 225, 2022)

Summary: Personalized cancer care based on tumour molecular characteristics has revolutionized treatment approaches and brought hope to many patients. The implementation of emerging technologies in molecular diagnostics, publicly funded in Norway, allows for comprehensive genomic profiling of tumours, offering more cancer patients the possibility of receiving precision cancer drugs through the national infrastructure called IMPRESS-Norway.